Yehualashet Awgichew Shewasinad, Yikna Berhan Begashaw
Pharmacology and Toxicology Unit, Department of Pharmacy, College of Health Sciences, Debre Berhan University, Debre Berhan, Ethiopia.
Diabetes Metab Syndr Obes. 2021 Apr 28;14:1841-1854. doi: 10.2147/DMSO.S304497. eCollection 2021.
Intestinal microbiota is established to be a crucial element in the control of human health, and keeping the symbiotic relationship between the human body and intestinal microbes will have paramount importance. A number of investigations illustrated that many chronic diseases are associated with intestinal micro-ecological disorders implying intestinal floras as an important component among the environmental factors, and perturbations in their composition are correlated with metabolic disorders, including obesity and diabetes mellitus (DM). Increased evidence suggests that alterations in the gut microbial ecosystem have been involved in part in the pathogenesis of both type 1 and type 2 DM. Short chain fatty acids (SCFAs), derived from microbiota, have been studied for their potential action in modulating CNS, gut barrier axis, and the immune system as a promising mechanism for the observed protective effects on diabetes pathogenesis. Besides, the role of bile acid (BA) stimulated receptors to have a significant role in liver metabolism, and pathophysiology of liver-based metabolic diseases has also been investigated. In the current review, we will try to summarize the correlation between intestinal microbiota and diabetes considering the existing current evidence revealing the role of gut microbiota in onset and disease progression.
肠道微生物群已被确认为控制人类健康的关键因素,维持人体与肠道微生物之间的共生关系至关重要。大量研究表明,许多慢性疾病与肠道微生态紊乱有关,这意味着肠道菌群是环境因素中的重要组成部分,其组成的扰动与代谢紊乱相关,包括肥胖和糖尿病(DM)。越来越多的证据表明,肠道微生物生态系统的改变在1型和2型糖尿病的发病机制中都起到了一定作用。源自微生物群的短链脂肪酸(SCFAs)因其在调节中枢神经系统、肠道屏障轴和免疫系统方面的潜在作用而受到研究,这是其对糖尿病发病机制具有保护作用的一种有前景的机制。此外,胆汁酸(BA)刺激受体在肝脏代谢中的重要作用以及基于肝脏的代谢性疾病的病理生理学也已得到研究。在本综述中,我们将根据现有证据总结肠道微生物群与糖尿病之间的相关性,这些证据揭示了肠道微生物群在发病和疾病进展中的作用。